CN101361726A - Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy - Google Patents
Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy Download PDFInfo
- Publication number
- CN101361726A CN101361726A CNA2008101959246A CN200810195924A CN101361726A CN 101361726 A CN101361726 A CN 101361726A CN A2008101959246 A CNA2008101959246 A CN A2008101959246A CN 200810195924 A CN200810195924 A CN 200810195924A CN 101361726 A CN101361726 A CN 101361726A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- cerebral
- ischemia
- preventing
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses the application of an astaxanthin in preparing drugs for preventing and curing brain stroke. Proved by experimental study related to astaxanthin cerebral ischemia resistance/ischemia-reperfusion injury in the invention, the astaxanthin can obviously improve behavioral symptoms caused by cerebral ischemia reperfusion injury of rats, decrease the volume of cerebral infarction and lower the cerebral edema of cerebral ischemia rats. Therefore, the astaxanthin can be used for preparing the drugs for preventing and curing brain stroke.
Description
Technical field:
The present invention relates to a kind of medical usage of astaxanthin.
Background technology:
Astaxanthin, promptly 3,3 '-dihydroxy-4,4 '-diketo-β, β '-carotene is the terpenes unsaturated compound, chemical molecular formula is C
40H
52O
4, extensively be present in nature, in most of Crustaceans and salmon fishes body, the leaf of plant, flower, really, and the feather of flamingo medium (Methods in Enzymology, 1992,213:386-391).What at present, the main source of natural astaxanthin and content were extremely abundant is algae, Haematocoocus Pluvialls and Fife's yeast.The safety of natural astaxanthin has obtained the approval of many countries.Astaxanthin has extremely strong antioxygenic property, for 500 times of vitamin E (Fisheries Science, 1996,62:134-137).Experiment shows that astaxanthin not only can directly be removed free radical, can also block the chain reaction of fatty acid.And different with other carotenoid be that astaxanthin can not become prooxidant (Redox Rep, 2004,9 (4): 181-191) under the hyperbaric oxygen condition.At present, in the research to superoxide dismutase-1 (SOD-1) prevention radical damage tissue, experimental results show that astaxanthin can improve the expression of this enzyme (J Exp Marine Biol Ecol, 2003,297 (1): 107-118).Astaxanthin can also prevent effectively phospholipid and other lipid peroxidating (J Agric Food Chem, 2000,48:1150).(Biol Pharm Bull, 2005,28 (1): 47-52) prove that also astaxanthin has significant neuroprotective such as Hussein.Except having extremely strong antioxygenic property, astaxanthin also has antiinflammatory action.Experimental results show that, astaxanthin can suppress the expression of generation, NO synthase (NOS), COX-2 (COX-2), tumor necrosis factor (TNF-α) and interleukin-1 ' beta ' (IL-1 β) inducing action of inflammatory cytokine class such as NO, PGE2 (PGE2), it in addition can suppress NO, PGE2, the serum levels of TNF-a and IL-1 β (Mol Cells, 2003,16 (1): 97-105).Mara company compares with natural astaxanthin and with other 26 kinds famous anti-inflammatory drug effects, and the result shows that the anti-inflammatory drug of 92% in astaxanthin and the investigation has equal effect or higher; Compare with 62 kinds of OTC (over-the-counter) anti-inflammatory agents that comprise aspirin, astaxanthin and 76% medicine wherein have equally valid or better (Technical Report TR, 3005.001.1999).These results illustrate that all the antiinflammatory action of astaxanthin can be used for the disease for the treatment of and preventing to be caused by inflammation.
The sickness rate of apoplexy is high always in the cardiovascular disease, and particularly cerebral infarction occupies the majority.Patients with cerebral apoplexy has 1/3 death soon after morbidity approximately, and survivor is disablement even self care ability because sequela such as hemiplegia, aphasia disable then.Apoplexy is as a kind of common disease, and the serious harm human beings'health affects human life quality, and brings heavy financial burden for patient family.Anti-cerebral ischemia apoplexy medicament categories is various, but most medicine just changes a certain link of the pathophysiological process of cerebral ischemia complexity, and the people is dissatisfied in addition for its curative effect, and some poisonous side effect of medicine is bigger.Therefore researching and developing a kind of safe and effective and new drug that can act on cerebral ischemia pathophysiological process too many levels will be the challenge of pendulum in face of ours.
Summary of the invention:
The object of the present invention is to provide the application of a kind of astaxanthin in preparation prevention and treatment apoplexy medicine.
Technical solution of the present invention is:
The application of astaxanthin in preparation prevention and treatment apoplexy medicine.
The present invention is through relevant astaxanthin anti-cerebral ischemia/reperfusion injury experimentation, experiment showed, behavior symptom that astaxanthin can obviously improve cerebral ischemia and cause, dwindles cerebral infarct volume, reduces the rats with cerebral ischemia cerebral edema.Therefore, astaxanthin can be used for preparing the medicine (comprising food) of preventing and treating apoplexy.
The invention will be further described below in conjunction with drawings and Examples.
Fig. 1 is that astaxanthin influences figure to cerebral ischemia re-pouring rat cerebral infarction volume moral in the test example.
Among Fig. 1: dosage group F astaxanthin high dose group in the A sham operated rats B matched group C nimodipine group D astaxanthin low dose group E astaxanthin
The specific embodiment:
The application of astaxanthin in preparation prevention and treatment apoplexy medicine.
The test example:
Astaxanthin is to the protective effect (" perfusion again " refers to recover supply of blood flow) of SD (Sprague-Dawley) cerebral ischemia
One, experiment material and method
1 material
1.1 laboratory animal: the male Sprague-Dawley of healthy adult (SD) rat, the cleaning level, body weight 240-260g, Nantong University's Experimental Animal Center provides.
1.2 main agents: astaxanthin is available from Sigma-Aldrich; Red tetrazolium (2,3,5-triphenyltetrazolium, TTC) powder is available from Shanghai Ling Jin Fine Chemical Co., Ltd.
2 methods
2.1 model preparation: with reference to middle cerebral artery line bolt method (middle cerebral artery occlusion, MCAo) the preparation Focal Ischemia-Reperfusion in Rats model of Longa EZ method and do improvement slightly.Nylon wire insertion depth average out to 18.5 native 0.5mm (counting) from the ECA crotch.Ligation is nylon wire fixedly, skin suture, and the bolt line stays lcm the end of a thread outward.Cervical region need not anaesthetized and cut to perfusion more once more behind the 2h, lifts the bolt line and show the nylon wire head end when resistance is arranged oneself reaches ICA bifurcated incision that blood flow is logical again.Sham operated rats bolt line only inserts 1.0cm, the same model group of all the other steps.The homonymy Hornor that occurs blood vessel embolism after animal the revives contralateral limbs dyskinesia of seeking peace is the model success.
2.2 neuroethology scoring: with reference to Zea Longa system scoring in 6 fens.Standards of grading: 0 minute: impassivity damage symptom; 1 minute: can not full extension offside fore paw; 2 minutes: turn-take laterally; 3 minutes: topple over to offside; 4 minutes: can not spontaneously walk loss of consciousness; 5 minutes: death.
2.3 the cerebral infarction kitchen range is measured: rat is got brain rapidly, removes rhinencephalon, cerebellum and low brain stem, freezing 10min, from the antinion to the occipital pole, do the continuous volume shape section of 2mm thickness, section is put in the 0.5%TTC solution, hatches 30 minutes in 37 ℃ of lucifuges, shakes section at interval in 5 minutes.Again section is placed 4% paraformaldehyde buffer fixing.Take pictures behind the 24h and import computer, use Image J﹠amp; The ScionImage image processing software calculates infarct size, and (red color area is a normal cerebral tissue, white area is an infarcted region), each brain sheet infarct size sum multiply by thickness (2mm) and is total Infarction volume, and the long-pending and full brain volume of cerebral infarction stove is than being the cerebral infarction percent by volume.
2.4 brain water content is measured: after ischemia 2h pours into 24h again, the rapid broken end of rat is got brain, survey the cerebral tissue moisture content with dried wet method, on ice cube, get brain rapidly, the cerebral tissue that takes out is placed in the culture dish that the moistening qualitative filter paper of normal saline is arranged in, in case water evaporates, the while is removed the pia mater encephali and the sludged blood on brain cortex surface fast.With analyzing the weight that Libra accurately takes by weighing two hemisphere, place 100 ℃ of baking boxs after 24 hours then, weigh once more, be relative water content with ((weight in wet base-dry weight)/weight in wet base) * 100%.
2.5 date processing and statistical analysis: all data are represented (mean scholar S.E.M) with mean ± standard error, adopt Stata8.0 statistical software deal with data, relatively adopt the t check between two groups.
Two, experimental result
The scoring of 1 neuroethology
Sham operated rats animal impassivity functional impairment, other each group all has neurologic impairment score value in various degree.After ischemia 2h poured into 24h again, nimodipine group and the scoring of matched group neuroethology had statistical significance (p＜0.05), and astaxanthin high dose group, middle dosage group and the scoring of matched group neuroethology have the difference (p＜0.001) of highly significant; Astaxanthin high dose group and nimodipine group also have statistical significance (p＜0.05).Illustrate that astaxanthin can obviously improve behavioristics's function of ischemia-reperfusion rat, and have dosage that dependency is arranged, action effect is better than nimodipine.(referring to table 1)
Table 1: astaxanthin is learned the influence of function scoring to the ischemia-reperfusion rat behavior
Annotate: compare * p＜0.05 with matched group; * p＜0.01; * * p＜0.001
Compare with the nimodipine group,
△P＜0.05
The mensuration of 2 cerebral infarction volumes
After ischemia 2h pours into 24h again, carry out TTC dyeing, slough is white in color in the infarcted region, and slough does not take on a red color.The brain district basically identical of infarcted region and MCA domination is found in observation, compare with matched group, each medicine group cerebral infarction percentage volume all obviously dwindles, and with the effect of astaxanthin high dose group significantly (p＜0.001), action effect obviously is better than nimodipine group (p＜0.01).(referring to table 2, Fig. 1).
Table 2: astaxanthin is to the influence of ischemia-reperfusion rat cerebral infarction volume
Annotate: compare * p＜0.05 with matched group; * p＜0.01; * * p＜0.00
Compare with the nimodipine group,
△P＜0.05;
△ △P＜0.01
The mensuration of 3 brain water contents
As seen from Table 3, the brain water content of nimodipine group is lower than matched group (p＜0.05), the astaxanthin low dose group is compared there was no significant difference (p〉0.05) with matched group, the brain water content of dosage group and high dose group significantly is lower than matched group (P＜0.01) in the astaxanthin, and action effect is better than nimodipine.Experimental result shows that astaxanthin can significantly reduce the water content of ischemical reperfusion injury cerebral tissue, alleviates ischemia side brain hemisphere edema degree.
Table 3: astaxanthin is to the influence of ischemia-reperfusion rat cerebral tissue water content
Annotate: compare * p＜0.05 with matched group; * p＜0.01
Compare with the nimodipine group,
△P＜0.05;
△ △P＜0.01
Three, experiment conclusion
Experimental result shows that astaxanthin can significantly improve the behavior symptom that the SD focal brain ischemia-reperfusion injury in rats causes, alleviates damage side cerebral edema, dwindles cerebral infarct volume, and action effect obviously is better than nimodipine.Thereby astaxanthin can be used for preparing medicine and the food of preventing and treating cerebral infarction.
Claims (1)
1, the application of astaxanthin in preparation prevention and treatment apoplexy medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101959246A CN101361726A (en) | 2008-09-05 | 2008-09-05 | Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008101959246A CN101361726A (en) | 2008-09-05 | 2008-09-05 | Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101361726A true CN101361726A (en) | 2009-02-11 |
Family
ID=40388458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101959246A Pending CN101361726A (en) | 2008-09-05 | 2008-09-05 | Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101361726A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| EP3153160A1 (en) | 2015-10-08 | 2017-04-12 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| CN112516119A (en) * | 2021-02-05 | 2021-03-19 | 云南维他源生物科技有限公司 | ASBD medicine composition for treating cerebral apoplexy and preparation and application thereof |
| CN112587512A (en) * | 2021-02-05 | 2021-04-02 | 云南维他源生物科技有限公司 | ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof |
| CN113143914A (en) * | 2021-04-19 | 2021-07-23 | 南通大学 | Application of brucea javanica picrol in preparation of medicine for treating cerebral ischemic stroke |
| CN114306319A (en) * | 2022-01-26 | 2022-04-12 | 中国科学院青岛生物能源与过程研究所 | Application of nervonic acid in repairing cerebral ischemia reperfusion injury |
-
2008
- 2008-09-05 CN CNA2008101959246A patent/CN101361726A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| EP3153160A1 (en) | 2015-10-08 | 2017-04-12 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
| CN112516119A (en) * | 2021-02-05 | 2021-03-19 | 云南维他源生物科技有限公司 | ASBD medicine composition for treating cerebral apoplexy and preparation and application thereof |
| CN112587512A (en) * | 2021-02-05 | 2021-04-02 | 云南维他源生物科技有限公司 | ASBDV pharmaceutical composition for treating cerebral apoplexy and preparation and application thereof |
| CN113143914A (en) * | 2021-04-19 | 2021-07-23 | 南通大学 | Application of brucea javanica picrol in preparation of medicine for treating cerebral ischemic stroke |
| CN114306319A (en) * | 2022-01-26 | 2022-04-12 | 中国科学院青岛生物能源与过程研究所 | Application of nervonic acid in repairing cerebral ischemia reperfusion injury |
| CN114306319B (en) * | 2022-01-26 | 2022-11-25 | 中国科学院青岛生物能源与过程研究所 | Application of nervonic acid in repairing cerebral ischemia reperfusion injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Fucoidan regulate blood glucose homeostasis in C57BL/KSJ m+/+ db and C57BL/KSJ db/db mice | |
| Liu et al. | Protective effect of thymoquinone improves cardiovascular function, and attenuates oxidative stress, inflammation and apoptosis by mediating the PI3K/Akt pathway in diabetic rats | |
| El-Hanoun et al. | Effect of bee venom on reproductive performance and immune response of male rabbits | |
| CN103750339B (en) | Saussurea involucrate culture health-care food and application thereof | |
| CN101361726A (en) | Use of astaxanthin in preparing medicine capable of preventing and treating cerebral apoplexy | |
| Dewi et al. | Guava (Psidium guajava) leaf extract enhances immunity, growth, and resistance against Vibrio parahaemolyticus in white shrimp Penaeus vannamei | |
| US20190358270A1 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
| Kadry et al. | Influence of some micronutrients and Citharexylum quadrangular extract against liver fibrosis in Schistosoma mansoni infected mice | |
| Chen et al. | Protective effect of nerolidol on lipopolysaccharide-induced acute lung injury through the inhibition of NF-κB activation by the reduction of p38 MAPK and JNK phosphorylation | |
| Rakuambo et al. | In vitro effect of medicinal plants used to treat erectile dysfunction on smooth muscle relaxation and human sperm | |
| Wang et al. | Effect of acetazolamide on cytokines in rats exposed to high altitude | |
| Farzamfar et al. | Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs | |
| RI et al. | The mechanisms of plant rhizome Curcuma longa action on carbohydrate metabolism in alloxan-induced diabetes mellitus rats | |
| Ayubi et al. | Curcumin: The active compound in turmeric has the potential to reduce pain intensity and increase range of motion during exercise-induced muscle damage | |
| CN103446166B (en) | Hepatic function remedial agent | |
| Al-Shudiefat et al. | The effects of some natural products compared to synthetic products on the metabolic activity, proliferation, viability, migration, and wound healing in sheep tenocytes | |
| Kadir et al. | Effects of monosodium glutamate on semen quality and the cytoarchitecture of the testis of adult Wistar rats | |
| Fulanetti et al. | Toxic effects of the administration of Mikania glomerata Sprengel during the gestational period of hypertensive rats | |
| Yu et al. | Effects of selenium-enriched Agaricus blazei Murill on liver metabolic dysfunction in mice, a comparison with selenium-deficient Agaricus blazei Murill and sodium selenite | |
| Mahmoud et al. | Prevention of tri-nitrobenzene of sulfonic acid-induced colitis in chicken by using extract of Aloe vera. | |
| Hashemi et al. | Morphometric study of the effect of Walnut (Juglans regia) leaf extract on cerebrum malformation in fetuses of diabetic rats | |
| Deckmann et al. | Common pregnancy complications and polyphenols intake: an overview | |
| CN100391476C (en) | Medicine composition for delaying senility and raising immunity and its prepn | |
| Huang et al. | The modulative effects of microcurrent electrical nerve stimulation on diabetic mice | |
| Omoya et al. | Comparative Effects of Garlic, Yogurt, Beniseed Liquor and Fresh Orange Juice on Induced Type-1 Diabetes Mellitus in Rabbits using Streptozotocin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090211 |